Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

20241 citationsJournal Articlegold Open Access

Authors

Alejo Rodríguez‐Vida · Centro de Investigación Biomédica en Red de Cáncer

Begoña P. Valderrama · Hospital Universitario Virgen del Rocío

Daniel Castellano · Research Institute Hospital 12 de Octubre

Álvaro Pinto · Hospital Universitario La Paz

Begoña Mellado · Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

J. Puente · Instituto de Investigación Sanitaria del Hospital Clínico San Carlos

Abstract

The hypothesis that induction avelumab could enhance the efficacy of subsequent ChT was not proven. Administering IO alone as induction before ChT is not an adequate strategy.

Topics & Keywords

Bladder and Urothelial Cancer Treatments Cancer Immunotherapy and Biomarkers Urinary and Genital Oncology Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: ESMO Open

Volume 9, Issue 9, pp. 103690-103690

DOI: 10.1016/j.esmoop.2024.103690

Field-Weighted Citation Impact: 0.58